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Introduction: Angiogenesis, or new blood vessel growth, is associated with various disease pathologies including
eye disease and cancer. In particular, our lab focuses on pathological vessel growth in corneal neovascularization
which is the leading cause of blindness in the developed world. Identifying effective anti-angiogenic molecules has
become important for developing alternative anti-angiogenic treatments for this and other related diseases. Since
endothelial cell migration has been shown to be a key indicator of angiogenesis in this disease, cell migration assays
have been a common method used to assess anti-angiogenic inhibitors and validate their activity ex vivo. However,
traditional migration assays, including the wound scratch assays and the trans-well migration assay, are labor
intensive and suffer from poor reproducibility. Over the last decade, microfluidic devices have been used in
migration assays and have resulted in steady improvements in workflow and assay reproducibility. Here we report
our findings from transitioning endothelial cell migration assays to a microfluidic platform which allows us place
endothelial cells in gradients of stimulants and inhibitors of cell migration and monitor cell migration via time-lapse
microscopy.
Method: Different migration assays, including the wound scratch assay, trans-well migration assay, a custom Yshaped microfluidics channel assay, and a commercial microfluidics platform gradient migration assay, were
performed with hemangioendothelioma cells (EOMA). Cells were treated with either complete growth medium or
serum free medium for four hours. For the wound scratch and Y-shaped microfluidics migration assay, migration
was measured by the change of wound area in four hours. Trans-well migration was measured by counting the
number of cells migrated from the membrane top surface to the bottom surface. Gradient migration assays using
the CellASIC ONIX microfluidic platform used time-lapse microscopy followed by individual cell tracking to
measure cell migration.
Result and Discussion: In wound scratch migration assays, EOMA migration in serum free medium was 50% of
the complete medium control (p < 0.005). Alternatively, trans-well migration assays weren’t able to show a
significant difference and were plagued by large uncertainties. The Y-shaped microfluidic channel assays provided
better reproducibility which was reflected in smaller error bars for assay replicates than either the wound scratch or
trans-well migration assays. We observed an 80% reduction in cell migration with EOMA in serum free medium
compare to the complete medium control (p < 0.002). In the CellASIC gradient assays, EOMA cells migration was
clearly toward the serum gradient as expected with significantly smaller uncertainties between the positive and
negative control. Moreover, assays with microfluidics devices require less amount of hands on operation time than
the traditional assays.
Conclusions: In conclusion, microfluidic migration assays perform better than the traditional cell migration assays
and are less labor intensive. With the gradient assays on the CellASIC ONIX platform, migration assays are semiautomated, provide internal controls (the same cells can be monitored with gradients in multiple directions) and
combined with automated tracking data analysis prevents analysis bias that as well as more reproducible results.

